31% af patienterne, som blev behandlet med venlafaxin, og hos 17% af patienterne, som fik placebo.
In clinical trials, adverse events seen on treatment discontinuation (tapering and post-tapering) occurred in approximately 35% of patients treated with venlafaxine and 17% of patients taking placebo.